SCHEMBL4307765

SCHEMBL4307765

O=C(Cc1cccs1)Nc1ccccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 9/20 0.62
AURKB Q96GD4 7/20 0.62
MAPT P10636 3/20 0.49
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 2/20 0.45
CASP6 P55212 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
ESR1 P03372 1/20 0.43
STAT3 P40763 1/20 0.43
ESR2 Q92731 1/20 0.43
TTK P33981 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307770 1.00 AURKA (0.62) AURKAAURKBMAPTKDM4ESMN1; SMN2
SCHEMBL4317391 0.90 AURKA (0.51) AURKAAURKBMAPTKDM4ESMN1; SMN2
SCHEMBL4317388 0.90 AURKA (0.51) AURKAAURKBMAPTKDM4ESMN1; SMN2
SCHEMBL4307935 0.84 AURKA (0.60) AURKAAURKBKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4307929 0.84 AURKA (0.60) AURKAAURKBKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4314375 0.82 MAPT (0.47) AURKAAURKBMAPTKDM4ESMN1; SMN2
SCHEMBL4314371 0.82 MAPT (0.47) AURKAAURKBMAPTKDM4ESMN1; SMN2
SCHEMBL4322645 0.81 AURKA (0.55) AURKAAURKBMAPTKDM4ETTK
SCHEMBL4322638 0.81 AURKA (0.55) AURKAAURKBMAPTKDM4ETTK
SCHEMBL4311170 0.78 HPGD (0.50) AURKAAURKBMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885MAPT 4175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.